Welcome to our dedicated page for Blade Air Mobility SEC filings (Ticker: BLDE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Strata Critical Medical, Inc., formerly Blade Air Mobility, Inc., files regulatory documents that document the company's transition from a broader air mobility platform to a critical medical business. The filings cover the completed Passenger business disposition, the corporate name change, Nasdaq-listed common stock under SRTA, and warrant-related capital-structure actions, including a Form 25 for removal of warrants from listing and registration.
Its 8-K reports and proxy materials disclose operating results from continuing operations, logistics and clinical revenue categories, material agreements, acquisition activity, credit arrangements involving operating subsidiaries such as Trinity Air Medical and Keystone Perfusion Services, and annual meeting governance matters. The record also includes exhibit filings, Inline XBRL cover data, and stockholder voting disclosures tied to the rebranded issuer.
Amir Cohen, Chief Accounting Officer and director of Strata Critical Medical, Inc. (SRTA), reported a grant of 11,844 fully vested restricted stock units (RSUs) on 08/29/2025. The RSUs vest and will be settled in shares of the issuer's Class A common stock at no cash price ($0). Following this transaction, Mr. Cohen beneficially owns 103,760 shares. The RSU grant is effective upon completion of the issuer's previously disclosed sale of its Passenger business to Joby Aero, Inc. under an Equity Purchase Agreement dated August 1, 2025. The Form 4 was signed by attorney-in-fact Melissa M. Tomkiel on 09/03/2025.
Andrew Lauck, a director of Strata Critical Medical, Inc. (ticker: SRTA), was granted 11,844 fully vested Restricted Stock Units (RSUs) on 08/29/2025. The filing states these RSUs will be settled in shares of the issuer's common stock and are effective upon completion of the issuer's previously announced sale of its Passenger business to Joby Aero, Inc., under the Equity Purchase Agreement dated August 1, 2025. Following this transaction, the reporting person beneficially owns 130,642 shares of Class A common stock. The Form 4 was signed by an attorney-in-fact on behalf of the reporting person on 09/03/2025.
Strata Critical Medical, Inc. filed an 8-K reporting several corporate governance changes, including a name change and the appointment of Co-Chief Executive Officers. The filing states the board will require independent members to elect a Lead Independent Director whenever the chairman is not independent or previously served as an officer, and describes the powers and duties of that role. The company amended bylaws to limit the number of stockholder-nominated director candidates at a meeting to the number of directors up for election and to revise procedural mechanics and disclosure obligations for nominations, proposals, and proxy solicitations. Additional bylaw changes address adjournments and align provisions with the Delaware General Corporation Law, plus clarifying and technical edits. The filing is dated August 29, 2025 and is signed by William A. Heyburn as Co-Chief Executive Officer and Chief Financial Officer.
Strata Critical Medical, Inc. filed an amended report to add details about compensation for its new Co-Chief Executive Officers, Melissa Tomkiel and William Heyburn, following the closing of an equity purchase agreement. Effective as of the closing, the board increased each executive’s base salary to $550,000.
Each co-CEO was also granted performance-based restricted stock units (PSUs) under the 2021 Omnibus Incentive Plan, with a target value of $500,000 tied to Passenger business financial targets over the 12 months after closing and $2,000,000 tied to company financial performance over a three-year period. The board approved enhanced equity treatment if either executive is terminated without Cause or resigns for Good Reason, including accelerated vesting of certain time-based awards and prorated vesting of performance awards based on actual results. These terms are reflected in offer letters entered into on August 28, 2025.
Scott M. Wunsch, an officer and director of Blade Air Mobility, Inc. (BLDE), reported a grant of 22,365 Restricted Stock Units (RSUs) on 08/14/2025. The RSUs are to be settled in shares of the company’s Class A common stock at $0 per share and will vest in full on December 8, 2025, subject to Wunsch's continued service. Following the reported grant, Wunsch beneficially owns 304,021 shares directly and an additional 382,987 shares indirectly through an LLC of which he is the sole member. The filing was signed by an attorney-in-fact on behalf of Wunsch on 08/18/2025.
Third Point LLC and Daniel S. Loeb report beneficial ownership of 5,000,000 shares of Blade Air Mobility, Inc., equal to 6.12% of the company's common stock. The percentage is calculated using the issuer's reported 81,695,605 shares outstanding as of July 29, 2025. Both reporting persons state shared voting and shared dispositive power for the 5,000,000 shares and report no sole voting or dispositive power.
The Schedule 13G filing includes a certification that the securities were not acquired to change or influence control of the issuer, clarifying the reporting persons' stated passive intent. The disclosure is material because it exceeds the 5% reporting threshold and identifies who holds meaningful shared influence over the issuer's voting rights.